Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 15/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 14/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 14/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26334441 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2379324 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6367254 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28949604 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6368277 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL21816672 | 0.98 | HTR2C (0.45) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL377976 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18081172 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1481267 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL15956717 | 0.78 | CHRNB2 (0.45) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | claimed |
| CN-1277824-C | Piperazine derivatives | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | CN | claimed |
| CN-1533382-A | Piperazine derivatives | - | 2004-09-29 | — | — | CN | claimed |
| CN-120051471-A | Novel heterocyclic compound | 首药控股(北京)股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4395892-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4395891-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| EP-4378936-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-06-05 | — | — | EP | disclosed |
| US-20130184285-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS (GB) | 2013-07-18 | — | — | US | disclosed |
| EP-1907374-B1 | Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GLAXO GROUP LTD. | 2010-10-07 | — | — | US | disclosed |
| EP-1789404-B1 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| CN-1277824-C | Piperazine derivatives | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | CN | disclosed |
| CN-1533382-A | Piperazine derivatives | - | 2004-09-29 | — | — | CN | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | HTR2C 3810/4885CHRNB2 4631/4885CHRNA4 4823/4885 |
| US-20090054456-A1 | BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE | GPR68, GPR88, GPR55 | HTR2C 68/4885CHRNB2 389/4885CHRNA4 478/4885 |
| US-20100256364-A1 | PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES | GPR68, GPR88, GIPR | HTR2C 437/4885CHRNB2 607/4885CHRNA4 746/4885 |
| US-20130184285-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | HTR2C 4622/4885CHRNB2 4852/4885CHRNA4 4700/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HTR2C 1240/4885CHRNB2 4577/4885CHRNA4 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.